AIMZ Investment Advisors’s Myriad Genetics MYGN Stock Holding History

AIMZ Investment Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Sell	36,060 -1,150	-3%	-$5.22K	0.06%	147
2026 Q1	$167K	Sell	37,210 -400	-1%	-$2.08K	0.05%	136
2025 Q4	$231K	Sell	37,610 -1,575	-4%	-$11.4K	0.07%	130
2025 Q3	$283K	Hold	39,185	–	–	0.09%	110
2025 Q2	$208K	Hold	39,185	–	–	0.07%	124
2025 Q1	$348K	Hold	39,185	–	–	0.12%	103
2024 Q4	$537K	Sell	39,185 -200	-0.5%	-$3.69K	0.19%	82
2024 Q3	$1.08M	Sell	39,385 -200	-0.5%	-$5.41K	0.37%	64
2024 Q2	$968K	Hold	39,585	–	–	0.35%	66
2024 Q1	$844K	Sell	39,585 -1,200	-3%	-$25.8K	0.31%	70
2023 Q4	$781K	Sell	40,785 -200	-0.5%	-$3.46K	0.32%	68
2023 Q3	$657K	Sell	40,985 -700	-2%	-$13.3K	0.29%	69
2023 Q2	$966K	Hold	41,685	–	–	0.42%	62
2023 Q1	$968K	Hold	41,685	–	–	0.43%	63
2022 Q4	$605K	Sell	41,685 -400	-1%	-$7.45K	0.29%	70
2022 Q3	$803K	Hold	42,085	–	–	0.41%	64
2022 Q2	$765K	Sell	42,085 -600	-1%	-$12.5K	0.37%	68
2022 Q1	$1.08M	Sell	42,685 -1,500	-3%	-$38.4K	0.44%	67
2021 Q4	$1.22M	Buy	44,185 +1,500	+4%	+$43.5K	0.47%	64
2021 Q3	$1.38M	Hold	42,685	–	–	0.62%	53
2021 Q2	$1.3M	Hold	42,685	–	–	0.59%	56
2021 Q1	$1.3M	Hold	42,685	–	–	0.64%	52
2020 Q4	$844K	Hold	42,685	–	–	0.44%	59
2020 Q3	$557K	Hold	42,685	–	–	0.33%	67
2020 Q2	$484K	Sell	42,685 -200	-0.5%	-$2.84K	0.31%	71
2020 Q1	$614K	Hold	42,885	–	–	0.48%	59
2019 Q4	$1.17M	Sell	42,885 -600	-1%	-$16.5K	0.76%	49
2019 Q3	$1.25M	Hold	43,485	–	–	0.86%	46
2019 Q2	$1.21M	Hold	43,485	–	–	0.83%	44
2019 Q1	$1.44M	Hold	43,485	–	–	0.99%	39
2018 Q4	$1.26M	Hold	43,485	–	–	0.98%	41
2018 Q3	$2M	Sell	43,485 -500	-1%	-$22.2K	1.29%	29
2018 Q2	$1.64M	Buy	43,985 +200	+0.5%	+$6.75K	1.16%	31
2018 Q1	$1.29M	Hold	43,785	–	–	0.94%	41
2017 Q4	$1.5M	Sell	43,785 -100	-0.2%	-$3.37K	1.13%	34
2017 Q3	$1.59M	Hold	43,885	–	–	1.3%	30
2017 Q2	$1.13M	Hold	43,885	–	–	0.95%	43
2017 Q1	$843K	Hold	43,885	–	–	0.71%	53
2016 Q4	$732K	Sell	43,885 -500	-1%	-$9.05K	0.65%	55
2016 Q3	$913K	Sell	44,385 -100	-0.2%	-$2.54K	0.82%	45
2016 Q2	$1.36M	Sell	44,485 -450	-1%	-$15.6K	1.25%	31
2016 Q1	$1.68M	Sell	44,935 -700	-2%	-$26.4K	1.53%	23
2015 Q4	$1.97M	Sell	45,635 -11,715	-20%	-$495K	1.8%	18
2015 Q3	$2.15M	Sell	57,350 -500	-0.9%	-$17.7K	1.97%	17
2015 Q2	$1.97M	Hold	57,850	–	–	1.71%	19
2015 Q1	$2.05M	Sell	57,850 -250	-0.4%	-$8.95K	1.75%	19
2014 Q4	$1.98M	Buy	+58,100	New	+$2.06M	1.76%	21

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AIMZ Investment Advisors's MYGN Position: Q2 2026 in Review

AIMZ Investment Advisors reduced its Myriad Genetics (MYGN) stake by 3.1% in Q2 2026, selling an estimated $5.22K and leaving 36,060 shares worth $206K. The position accounts for 0.06% of the portfolio, ranked #147.

AIMZ Investment Advisors first reported a position in MYGN in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.15M in Q3 2015. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

AIMZ Investment Advisors held 36,060 shares of Myriad Genetics worth $206K as of Q2 2026.
AIMZ Investment Advisors sold 1,150 Myriad Genetics shares in Q2 2026, an estimated $5.22K.
Myriad Genetics made up 0.06% of AIMZ Investment Advisors's portfolio in Q2 2026, its #147 holding.
AIMZ Investment Advisors first reported a position in Myriad Genetics in Q4 2014 and has held it in 47 quarters since.
AIMZ Investment Advisors's Myriad Genetics position peaked at $2.15M in Q3 2015.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on AIMZ Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.